Dr. Shah on Emerging Developments in MCL

Video

In Partnership With:

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses some of the emerging developments on the horizon in mantle cell lymphoma (MCL).

Bijal D. Shah, MD, medical oncology, Moffitt Cancer Center, discusses some of the emerging developments on the horizon in mantle cell lymphoma (MCL).

The most complicated patient with MCL is the ibrutinib-resistant patient, particularly those who develop ibrutinib resistance early in the disease course, Shah says. These individuals tend to have extraordinarily aggressive lymphoma that tend to be very chemotherapy resistant. Data from Moffitt Cancer Center show that the median survival when someone progresses on ibrutinib is approximately 2 months. About three-fourths of the patients who die within 2 months, die within the first 2 or 3 weeks.

Researchers have been profiling patients with MCL to try to understand what drugs work and what do not.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD